Interestingly, our study highlights significant prognostic value for LAMTOR4 expression in combination with common genomic alterations such as PTEN loss and ERG gain, even when adjusted to Gleason Grade Groups, supporting the potential utilization of combined biomarkers for stratifying men with prostate cancer into various risk groups for lethal disease and overall survival. The gene discussed is LAMTOR4; the disease is Familial prostate cancer.